title: Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake.
abstract: The aim of this study was to optimise radioiodine therapy of diffuse and nodular toxic goitre by calculation of the radiation dose delivered to the thyroid on the basis of the pretreatment technetium-99m pertechnetate thyroid uptake under thyrotropin suppression (TcTU(s)). The TcTU(s) value serves as a substitute for the non-suppressible iodine turnover and the functional autonomous mass. Marinelli's formula was used to calculate tissue absorbed doses of 150 Gy, 200 Gy, 250 Gy and 300 Gy to the thyroids of 438 patients with multifocal and disseminated autonomy. The mean age of patients was 70+/-9 years, and the mean thyroid volume was 54+/-26 ml. Two hundred and sixty-one of the patients had at least one documented previous episode of overt hyperthyroidism. Tissue absorbed doses were adapted to the pretreatment TcTU(s): 150 Gy for a TcTU(s) of 1.5%-2.49%, 200 Gy for a TcTU(s) of 2.5%-3.49%, 250 Gy for a TcTU(s) of 3.5%-4.49% and 300 Gy for a TcTU(s) of > or =4.5%. Normalisation of TcTU(s) and thyrotropin (TSH), thyroid volume reduction and frequency of hypothyroidism and recurrent hyperthyroidism were evaluated 1 year after a single radioiodine therapy. The presented dose strategy resulted in normalisation of TcTU(s) in 96% and an increase in TSH to the normal range in 92%. Recurrent hyperthyroidism was observed in only five patients. Thyroid volume decreased from 54+/-26 before treatment to 34+/-20 ml, a mean reduction of 37%. The frequency of hypothyroidism, at 0.9%, was encouragingly low. Dose selection in accordance with pretreatment TcTU(s) can be recommended for elimination of functional autonomous tissue with a single radioiodine therapy in patients of advanced age with enlarged thyroid glands and relevant autonomous masses who are at risk of developing iodine-induced hyperthyroidism.
authors.affiliation: Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany. michael.reinhardt@ukb.uni-bonn.de
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Reinhardt
authors.forename: Alexius
authors.initials: A
authors.lastname: Joe
authors.forename: Dirk
authors.initials: D
authors.lastname: von Mallek
authors.forename: Martina
authors.initials: M
authors.lastname: Zimmerlin
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Manka-Waluch
authors.forename: Holger
authors.initials: H
authors.lastname: Palmedo
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Krause
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000532:radiotherapy*; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D013670:Sodium Pertechnetate Tc 99m / Q000493:pharmacokinetics; D018709:Statistics, Nonparametric; D013972:Thyrotropin / Q000032:analysis; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood; D014463:Ultrasonography
chemical_list: D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013972:Thyrotropin; D013670:Sodium Pertechnetate Tc 99m; D013974:Thyroxine